Univariate analysis | Multivariate analysis model 3 (with both BATM and BTSM) | |||||
---|---|---|---|---|---|---|
p | HR | 95% CI | p | HR | 95% CI | |
Age (<50 years vs. ≥ 50 years) | 0.055 | 1.746 | 0.987–3.088 | 0.741 | 0.843 | 0.305–2.326 |
Molecular subtype (LuA-like vs. LuB-like vs. TNBC vs. HER2 Lu-like vs. HER2 nonLu like) | 0.03* | 1.213 | 1.018–1.444 | 0.185 | 1.351 | 0.866–2.107 |
Grading (G1 vs. G2 vs. G3) | 0.003* | 1.763 | 1.056–2.945 | 0.405 | 1.403 | 0.633–3.110 |
Tumor foci (unifocal vs. multifocal and multicentric) | 0.889 | 0.971 | 0.642–1.469 | n.i. | n.i. | n.i. |
Tumor size (pT1 vs. pT2 vs. pT3 vs. pT4) | 5.573E−13* | 2.064 | 1.695–2.513 | 0.001* | 1.827 | 1.269–2.631 |
Axillary lymph node status (pN0 vs. pN1 vs.pN2) | 0.002* | 1.859 | 1.256–2.749 | 0.285 | 1.650 | 0.659–4.131 |
ER status (ER− vs. ER+) | 0.026* | 0.589 | 0.369–0.940 | 0.604 | 0.718 | 0.205–2.515 |
PR status (PR− vs. PR+) | 0.088 | 0.697 | 0.461–1.054 | n.i. | n.i. | n.i. |
HER2 status (HER2− vs. HER2+) | 0.079 | 1.667 | 0.942–2.952 | n.i. | n.i. | n.i. |
Expression of ki-67 (ki-67 ≤ 14% vs. ki-67>14%) | 0.891 | 1.040 | 0.588–1.840 | n.i. | n.i. | n.i. |
BATMs (low vs. high) | 0.001* | 2.483 | 1.474–4.182 | 0.004* | 4.464 | 1.624–12.269 |
BTSMs (low vs. high) | 0.025* | 2.445 | 1.117–5.354 | 0.737 | 0.813 | 0.243–2.721 |